229 related articles for article (PubMed ID: 25555283)
1. Ranolazine: Drug overview and possible role in primary microvascular angina management.
Cattaneo M; Porretta AP; Gallino A
Int J Cardiol; 2015 Feb; 181():376-81. PubMed ID: 25555283
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Yuriivna Osovska N; Vitaliivna Kuzminova N
Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
[TBL] [Abstract][Full Text] [Related]
3. Efficiency of ranolazine in the patient with microvascular angina, atrial fibrillation and migraine.
Osovska NY; Kuzminova NV
Wiad Lek; 2016; 69(6):832-837. PubMed ID: 28214825
[TBL] [Abstract][Full Text] [Related]
4. Management of microvascular angina pectoris.
Lanza GA; Parrinello R; Figliozzi S
Am J Cardiovasc Drugs; 2014 Feb; 14(1):31-40. PubMed ID: 24174173
[TBL] [Abstract][Full Text] [Related]
5. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
Mehta PK; Goykhman P; Thomson LE; Shufelt C; Wei J; Yang Y; Gill E; Minissian M; Shaw LJ; Slomka PJ; Slivka M; Berman DS; Bairey Merz CN
JACC Cardiovasc Imaging; 2011 May; 4(5):514-22. PubMed ID: 21565740
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
Rosano GMC; Vitale C; Volterrani M
Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
[TBL] [Abstract][Full Text] [Related]
7. [Coronary microvascular dysfunction. An update].
Lamendola P; Di Franco A; Tarzia P; Milo M; Laurito M; Lanza GA
Recenti Prog Med; 2011 Sep; 102(9):329-37. PubMed ID: 21947187
[TBL] [Abstract][Full Text] [Related]
8. Ranolazine for Symptomatic Management of Microvascular Angina.
Rayner-Hartley E; Parvand M; Humphries KH; Starovoytov A; Park JE; Sedlak T
Am J Ther; 2020; 27(2):e151-e158. PubMed ID: 29746286
[TBL] [Abstract][Full Text] [Related]
9. Microvascular angina: angina that predominantly affects women.
Park JJ; Park SJ; Choi DJ
Korean J Intern Med; 2015 Mar; 30(2):140-7. PubMed ID: 25750553
[TBL] [Abstract][Full Text] [Related]
10. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
Melloni C; Newby LK
Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
[TBL] [Abstract][Full Text] [Related]
11. The use of ranolazine in non-anginal cardiovascular disorders: A review of current data and ongoing randomized clinical trials.
Mihos CG; Krishna RK; Kherada N; Larrauri-Reyes M; Tolentino A; Santana O
Pharmacol Res; 2016 Jan; 103():49-55. PubMed ID: 26546970
[TBL] [Abstract][Full Text] [Related]
12. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
[TBL] [Abstract][Full Text] [Related]
13. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Ahmed B; Mondragon J; Sheldon M; Clegg S
Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
[TBL] [Abstract][Full Text] [Related]
14. Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis: The MARINA Randomized, Double-Blinded, Controlled Pilot Trial.
Koh JS; Hung OY; Eshtehardi P; Kumar A; Rabah R; Raad M; Kumar S; Chaudhry S; Gupta S; Hosseini H; Brilakis E; Corban M; Sabbak N; Burnett GM; Liu C; Mehta PK; Quyyumi AA; Samady H
Circ Cardiovasc Interv; 2020 Dec; 13(12):e008204. PubMed ID: 33272036
[TBL] [Abstract][Full Text] [Related]
15. New Anti-Anginal Drugs: Ranolazine.
Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
[TBL] [Abstract][Full Text] [Related]
16. Ranolazine and Microvascular Angina by PET in the Emergency Department: Results From a Pilot Randomized Controlled Trial.
Safdar B; D'Onofrio G; Dziura J; Russell RR; Johnson C; Sinusas AJ
Clin Ther; 2017 Jan; 39(1):55-63. PubMed ID: 28081848
[TBL] [Abstract][Full Text] [Related]
17. Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
Ambrosio G; Tamargo J; Grant PJ
Diab Vasc Dis Res; 2016 Mar; 13(2):98-112. PubMed ID: 26873904
[TBL] [Abstract][Full Text] [Related]
18. Ranolazine as an additional antianginal therapy in patients with stable symptomatic coronary artery disease.
Sanfuentes B; Bulnes JF
Medwave; 2018 Nov; 18(7):e7332. PubMed ID: 30451816
[TBL] [Abstract][Full Text] [Related]
19. Coronary Microvascular Dysfunction, Microvascular Angina, and Management.
Löffler AI; Bourque JM
Curr Cardiol Rep; 2016 Jan; 18(1):1. PubMed ID: 26694723
[TBL] [Abstract][Full Text] [Related]
20. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.
Villano A; Di Franco A; Nerla R; Sestito A; Tarzia P; Lamendola P; Di Monaco A; Sarullo FM; Lanza GA; Crea F
Am J Cardiol; 2013 Jul; 112(1):8-13. PubMed ID: 23558043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
